CardiaCare

CardiaCare is an innovative startup focusing on developing a wearable therapeutic solution for reducing the burden of Atrial Fibrillation (AFib), which is currently considered a rising epidemic affecting millions worldwide. Utilizing noninvasive peripheral neuromodulation, CardiaCare's technology aims to mediate a cardiovascular antiarrhythmic response, thus reducing the AFib burden. The approach involves a closed-loop system integrating monitoring and therapy. Founded in 2018 and headquartered in Israel, the company has gained attention and support from investors. Its recent Seed Round investment on 18 September 2023 was backed by Solardis Health Ventures, showcasing the excitement and confidence the investors have in the potential of the company. With expert leadership in place, CardiaCare is gearing up for its first regulatory human clinical trial, marking a significant milestone in its journey to bring this groundbreaking technology to the market. This substantial support and focus on groundbreaking medical technologies position CardiaCare as a promising player in the Health Care industry.